

Liste

Studienübersicht Tumorzentrum KSB

Geltungsbereich: Tumorzentrum	Herausgeber: Tumorzentrum	Erstellt am: 10.02.2026	Freigegeben am: 07.07.2026
---	-------------------------------------	-----------------------------------	--------------------------------------

Sponsor Study Name	Title	Principal Investigator Clinical Research Coordinator	Studien- eröffnung	Ende Einschluss
Hämatologische Studien				
Swiss Cancer Institute (SCI) EMCL Register - on hold -	The Registry of the European Mantle Cell Lymphoma study group – MCL: Disease pattern, treatment algorithms and mechanisms of relapse	Dr. Veronika Ballova Veronika.Ballova@ksb.ch Dr. Birthe Lohmann Birthe.Lohmann@ksb.ch	29.01.2020	
Inselspital Bern MDS-Registry	Multicentre observational study of MDS patients in Switzerland – Swiss MDS Registry.	Dr. Veronika Ballova Veronika.Ballova@ksb.ch Beatrice Walter Beatrice.WalterHoerler@ksb.ch	31.01.2022	Stopp I- CARE Subprojekt am 31.12.23
Regeneron R1979-HM-2298 OLYMPIA-1	A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 Bispecific Antibody Versus Investigator's Choice in Previously Untreated Participants with Follicular Lymphoma (OLYMPIA-1)	Dr. Veronika Ballova Veronika.Ballova@ksb.ch Severine Miszak SeverineDominique.Miszak@ksb.ch	20.08.2024	22.08.2025
Pfizer C1071007 MagnetisMM-7	A randomized, 2-Arm, Phase 3 study of Elranatamab (PF-06863135) versus Lenalidomide in patients with newly diagnosed multiple myeloma after undergoing autologous stem-cell transplantation	Dr. Veronika Ballova Veronika.Ballova@ksb.ch Severine Miszak SeverineDominique.Miszak@ksb.ch	19.11.2024	Q3 2025
SCI CLL 18	A phase 3 multicenter, randomized, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes.	Dr. Veronika Ballova Veronika.Ballova@ksb.ch Severine Miszak SeverineDominique.Miszak@ksb.ch	16.12.2025	

Sponsor Study Name	Title	Principal Investigator Clinical Research Coordinator	Studien- eröffnung	Ende Einschluss
Merck Sharp & Dohme LLC MK-2140-010	A randomized, open-label, multicenter, phase 3 study of Zilovetamab Vedotin (MK-2140) in combination with R-CHP versus R-CHOP in participants with previously untreated Diffuse Large B-Cell Lymphoma (DLBCL).	Dr. Kristina Fritsch Kristina.Fritsch@ksb.ch Susanne Glienke Susanne.Glienke@ksb.ch	18.07.2025	
Lungen-Karzinome				
eVOLVE Meso, AstraZeneca	A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed Versus Platinum plus Pemetrexed or Nivolumab plus Ipilimumab in Participants with Unresectable Pleural Mesothelioma (eVOLVE-Meso)	Prof. Sacha Rothschild Sacha.Rothschild@ksb.ch Susan Groth Susan.Groth@ksb.ch	01.12.2023	14.01.2026
USB/SCI LCNEC	Treatment patterns and outcomes in patients with advanced large cell neuroendocrine carcinoma of the lung (LCNEC).	Dr. Christine Waibel Christine.Waibel@ksb.ch Jana Hagenbucher Jana.Hagenbucher@ksb.ch	07/2025	
SCLC				
ETOP 23-22 RAISE	A single-arm phase II trial of the addition of niraparib to anti-PD-L1 antibody maintenance in patients with SLFN11-positive, extensive-disease small cell lung cancer.	Dr. Christine Waibel Christine.Waibel@ksb.ch Severine Miszak SeverineDominique.Miszak@ksb.ch	03/2023	
ETOP 19-25 START	A multicentre phase II trial of tarlatamab in patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2.	Prof. Sacha Rothschild Sacha.Rothschild@ksb.ch Susan Groth Susan.Groth@ksb.ch	15.04.2026	
Amgen 20230016 Taratamab	A Phase 3, Randomized, Double-blinded, placebo-controlled, Multicenter study of Tarlatamab therapy in subject with limited-stage small-cell lung cancer who have not progressed following concurrent chemoradiation therapy (DeLLphi-306)	Prof. Sacha Rothschild Sacha.Rothschild@ksb.ch Severine Miszak SeverineDominique.Miszak@ksb.ch	09/2024	27.06.2025

Sponsor Study Name	Title	Principal Investigator Clinical Research Coordinator	Studien- eröffnung	Ende Einschluss
Amgen 20240092	A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects with Small Cell Lung Cancer (SCLC) (DeLLphi-309)	Prof. Sacha Rothschild Sacha.Rothschild@ksb.ch Susanne Glienke Susanne.Glienke@ksb.ch	03.02.2025	15.08.2025
NSCLC				
ETOP 25-23 ADOPT	An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant Durvalumab after neoadjuvant chemotherapy plus Durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC.	Prof. Sacha Rothschild Sacha.Rothschild@ksb.ch Susan Groth Susan.Groth@ksb.ch	12/2024	
BioNTech BNT327-066	A Phase II/III, multisite, randomized trial of BNT327 in combination with chemotherapy and other investigational agents in first-line NSCLC.	Dr. Christine Waibel Christine.Waibel@ksb.ch Beatrice Walter Beatrice.WalterHoerler@ksb.ch	17.04.2026	
SCI 18/24	Reduced-dose carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab monotherapy in treatment naive older and frail patients with metastatic NSCLC with PD-L1 < 50%. A multicentre randomized open-label phase II trial.	Prof. Sacha Rothschild Sacha.Rothschild@ksb.ch Beatrice Walter Beatrice.WalterHoerler@ksb.ch	08.05.2026	
BMS CA244-0010 IZABRIGHT-Lung01	A randomized, open-label, phase 2/3 study of Izalontamab Brengitecan versus Platinum-based chemotherapy in patients with EGFR-mutated NSCLC and disease progression on EGFR tyrosine kinase inhibitor therapy.	Prof. Sacha Rothschild Sacha.Rothschild@ksb.ch Beatrice Walter Beatrice.WalterHoerler@ksb.ch	21.01.2026	
SCI 16/18	Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD-L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III(N2) non-small cell lung cancer (NSCLC). A multicenter phase II trial.	Dr. Christine Waibel Christine.Waibel@ksb.ch Susan Groth Susan.Groth@ksb.ch	28.04.2020	31.07.2025
Daiichi-Sankyo Tropion-LUNG08	A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)	Dr. Christine Waibel Christine.Waibel@ksb.ch Beatrice Walter Beatrice.WalterHoerler@ksb.ch	09.09.2022	28.04.2026

Sponsor Study Name	Title	Principal Investigator Clinical Research Coordinator	Studien- eröffnung	Ende Einschluss
Novocure EF-44 LUNAR 2	LUNAR-2: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant with Pembrolizumab and Platinum Based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer	Prof. Sacha Rothschild Sacha.Rothschild@ksb.ch Susanne Glienke Susanne.Glienke@ksb.ch	11/2024	15.04.2026
NSCLC with actionable genomic alterations				
Amgen 20190341 CodeBreakK202	A phase 3, multicenter, randomized, open-label study evaluating efficacy of Sotorasib Platinum doublet combination versus Pembrolizumab Platinum doublet combination as a front-line therapy in subjects with stage IV or advanced stage IIIB/C nonsquamous non-small cell lung cancers, negative for PD-L1, and positive for KRAS p.G12C.	Prof. Sacha Rothschild Sacha.Rothschild@ksb.ch Beatrice Walter Beatrice.WalterHoerler@ksb.ch	18.12.2023	
Bayer 22615 SOHO-02	Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer with HER2-activating mutations.	Prof. Sacha Rothschild Sacha.Rothschild@ksb.ch Severine Miszak SeverineDominique.Miszak@ksb.ch	Q3/2024	
Roche KRAScendo-2	A phase III, randomized, open-label, multicenter study evaluating the efficacy and safety of Divarasib + Pembrolizumab compared with Pembrolizumab + Pemetrexed + Carboplatin or Cisplatin in patients with previously untreated, KRAS G12C-positive, advanced or metastatic non-squamous NSCLC.	Prof. Sacha Rothschild Sacha.Rothschild@ksb.ch Severine Miszak SeverineDominique.Miszak@ksb.ch	25.03.2026	
Lilly Sunray-02	A Phase 3, multicenter, double-blind, placebo-controlled study assessing the efficacy and safety of Olomorasib in combination with SOC immunotherapy in participants with resected or unresectable KRAS G12C-mutant NSCLC.	Prof. Sacha Rothschild Sacha.Rothschild@ksb.ch Severine Miszak SeverineDominique.Miszak@ksb.ch	14.04.2026	
Revolution Medicine RASolve 301	Phase III multicenter, open label, randomized study of RMC-6236 versus Docetaxel in patients with previously treated unresectable or metastatic NSCLC harboring RAS mutations.	Prof. Sacha Rothschild Sacha.Rothschild@ksb.ch Dr. Alena Belohlavek Alena.Belohlavek@ksb.ch	04.03.2026	
SCI LuCa 2	Retrospective and prospective registry of patients with metastatic NSCLC harboring typical and atypical EGFR mutations.	Dr. Christine Waibel Christine.Waibel@ksb.ch Severine Miszak SeverineDominique.Miszak@ksb.ch	10.07.2023	

Sponsor Study Name	Title	Principal Investigator Clinical Research Coordinator	Studien- eröffnung	Ende Einschluss
AstraZeneca SAFFRON	A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON)	Prof. Sacha Rothschild Sacha.Rothschild@ksb.ch Beatrice Walter Beatrice.WalterHoerler@ksb.ch	03/2022	31.10.2025
BMS Trident CA127-1030	Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants with Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)	Prof. Sacha Rothschild Sacha.Rothschild@ksb.ch Beatrice Walter Beatrice.WalterHoerler@ksb.ch	10/2023	15.05.2025
Gynäkologische Studien				
Expression IX	Weltweite UMFRAGE zum Langzeitüberleben bei gynäkologischer Krebserkrankung	Prof. Martin Heubner Martin.Heubner@ksb.ch Susanne Sonntag Susanne.Sonntag@ksb.ch	04.05.2022	
ENGOT Swiss Go MATAO	Maintenance Therapie/ Erhaltungstherapie mit Aromatase-hemmer für Patientinnen mit epitheliale Ovarialkarzinom: eine randomisierte doppelblinde Placebo-kontrollierte multizentrische Phase III Studie.	Prof. Martin Heubner Martin.Heubner@ksb.ch Carina Rofner Carina.Rofner@ksb.ch	11/2020	
OvCar (SCI)	Ein retrospektives und prospektives Register von Patientinnen mit Eierstockkrebs.	Prof. Martin Heubner Martin.Heubner@ksb.ch Carina Rofner Carina.Rofner@ksb.ch	02/2024	
STREAM-I	Chirurgische Behandlung bei fortgeschrittenem und rezidivierendem Endometriumkarzinom Managementbewertung präoperativer klinischer und translationaler Selektionskriterien für die zytoreduktive Chirurgie bei Endometriumkarzinom	Prof. Martin Heubner Martin.Heubner@ksb.ch Carina Rofner Carina.Rofner@ksb.ch	20.08.2024	
ESGO/Swiss AGO HSM	Zentralisierung und Bewertung der Versorgungsqualität in der gynäkologischen Onkologie im Rahmen des Prozesses der hochspezialisierten Medizin	Prof. Martin Heubner Martin.Heubner@ksb.ch Carina Rofner Carina.Rofner@ksb.ch	28.01.2025	

Sponsor Study Name	Title	Principal Investigator Clinical Research Coordinator	Studien- eröffnung	Ende Einschluss
ADOC	Beeinflusst eine Autoimmunerkrankung nach Diagnose eines Ovarialkarzinoms die Prognose? Eine multizentrische retrospektive Kohortenstudie	Prof. Martin Heubner Martin.Heubner@ksb.ch Carina Rofner Carina.Rofner@ksb.ch	03/2025	
OV Precision	Eine randomisiert kontrollierte Schweizer Studie zur Untersuchung des Nutzens einer Biologie-spezifischen Krebstherapie bei fortgeschrittenem schwer therapierbarem Eierstockkrebs	Prof. Martin Heubner Martin.Heubner@ksb.ch Christin Kiesewetter Christin.Kiesewetter@ksb.ch	20.05.2025	
Mamma-Karzinome				
Oracle Destiny Breast Respond	A prospective, non-interventional study (NIS) with Trastuzumab Deruxtecan for patients with HER2-(ultra)low expressing unresectable and/or metastatic breast cancer accompanied by a disease registry of patients treated with conventional chemotherapy.	Dr. Tilly Nothhelfer Tilly.Nothhelfer@ksb.ch Susan Groth Susan.Groth@ksb.ch	Q4/2024	
Taxis (SCI 23/16 USB)	Chirurgische Achsel-Lymphknotenentfernung mit der Option „ausgedehnte Operation“ oder „Radiotherapie“ bei Brustkrebspatienten mit bestehendem Lymphknotenbefall der Achselhöhle.	Prof. Cornelia Leo Cornelia.Leo@ksb.ch Christin Kiesewetter Christin.Kiesewetter@ksb.ch	20.11.2018	30.12.2025
SCI 23/18 VISION 1 Hirslanden	Vakuum-assistierte Biopsie vor Tumoroperation.	Prof. Cornelia Leo Cornelia.Leo@ksb.ch Christin Kiesewetter Christin.Kiesewetter@ksb.ch	06/2020 Restart am 23.08.2022	
IRMA (Frauenfeld)	Komplikationen und Lebensqualität nach Sofortrekonstruktion der Brust.	Prof. Cornelia Leo Cornelia.Leo@ksb.ch Silke Callies Silke.Callies@ksb.ch	01/2020	13.05.2025
EUBREAST MELODY	Internationale, multizentrische, prospektive Studie über verschiedene chirurgische Techniken bei nicht tastbaren Brustläsionen.	Prof. Cornelia Leo Cornelia.Leo@ksb.ch Silke Callies Silke.Callies@ksb.ch	21.06.2023	

Sponsor Study Name	Title	Principal Investigator Clinical Research Coordinator	Studien- eröffnung	Ende Einschluss
IIT PRoScreen	Untersuchung der Auswirkung eines polygenen Risikoscores auf die Brustkrebsvorsorge.	Prof. Cornelia Leo Cornelia.Leo@ksb.ch Susanne Sonntag Susanne.Sonntag@ksb.ch	06/2023	
PREcoopERA (IBCSG 67/22)	Eine Window-of-Opportunity-Studie mit Giredestrant +/- Triptorelin vs. Anastrozol + Triptorelin bei prämenopausalen Patientinnen mit ER-positivem/HER2-negativem Brustkrebs im Frühstadium	Prof. Cornelia Leo Cornelia.Leo@ksb.ch Carina Rofner Carina.Rofner@ksb.ch	03/2024	15.08.2025
AstraZeneca D8535C00001 Cambria2	Eine offene, randomisierte Phase-III-Studie zur Bewertung der Wirksamkeit und Sicherheit von Camizestrant (AZD9833, ein oraler selektiver Östrogenrezeptor-Degrader der nächsten Generation) im Vergleich zur endokrinen Standardtherapie als adjuvante Behandlung für Patienten mit ER+/HER2 - Brustkrebs im Frühstadium und einem mittelhohen o. hohen Rückfallrisiko, die eine endgültige lokoregionäre Behandlung abgeschlossen haben und keine Anzeichen einer Krankheit haben.	Prof. Cornelia Leo Cornelia.Leo@ksb.ch Christin Kiesewetter Christin.Kiesewetter@ksb.ch	09/2024	
Tropion-Breast04 (TB04) (AstraZeneca D926QC00001)	Eine offene, randomisierte Phase-III-Studie mit neoadjuvanten Datopotamab Deruxtecán (Dato-DXd) plus Durvalumab, gefolgt von adjuvanten Durvalumab mit oder ohne Chemotherapie im Vergleich zu neoadjuvanten Pembrolizumab plus Chemotherapie, gefolgt von adjuvanten Pembrolizumab mit oder ohne Chemotherapie zur Behandlung erwachsener Patienten mit zuvor unbehandeltem, dreifach negativem oder Hormonrezeptor-niedrigem/HER2-negativem Brustkrebs.	Prof. Cornelia Leo Cornelia.Leo@ksb.ch Carina Rofner Carina.Rofner@ksb.ch	12.06.2024	06/2025
Pfizer C4391025	Eine interventionelle, offene, randomisierte, multizentrische Phase-II-Studie zu PF-07220060 plus Letrozol im Vergleich zu Letrozol allein bei postmenopausalen Frauen ab 18 Jahren mit Hormonrezeptor-positivem, HER2-negativem Brustkrebs im neoadjuvanten Setting.	Prof. Cornelia Leo Cornelia.Leo@ksb.ch Jeannine Breindl Jeannine.Breindl@ksb.ch	11.02.2025	11.07.2025
Stemline Therapeutics ELEGANT	Elacestrant im Vergleich zur endokrinen Standardtherapie bei Frauen und Männern mit Lymphknoten-positivem, Estrogenrezeptor-positivem, HER2-negativem Brustkrebs im Frühstadium mit hohem Rezidivrisiko	Prof. Cornelia Leo Cornelia.Leo@ksb.ch Jeannine Breindl Jeannine.Breindl@ksb.ch Christin Kiesewetter Christin.Kiesewetter@ksb.ch	23.07.2025	

Sponsor Study Name	Title	Principal Investigator Clinical Research Coordinator	Studien- eröffnung	Ende Einschluss
Urogenital-Karzinome				
SCI 06/19	Intravesical recombinant BCG followed by perioperative chemo-immunotherapy for patients with muscle-invasive bladder cancer (MIBC). A multicenter, single-arm phase II trial	Dr. Andreas Erdmann Andreas.Erdmann@ksb.ch Severine Miszak SeverineDominique.Miszak@ksb.ch	20.05.2022	01.05.2025
HOCH Health Kantonsspital St. Gallen SCI 63/12	Prospective cohort study with collection of clinical data, serum and plasma of patients with prostate disease.	Dr. Andreas Erdmann Andreas.Erdmann@ksb.ch Susan Groth Susan.Groth@ksb.ch	28.11.2014	
SCI 08/23	Addition of Darolutamide to first line treatment of mCRPC: a randomized open label phase II trial.	Dr. Andreas Erdmann Andreas.Erdmann@ksb.ch Severine Miszak SeverineDominique.Miszak@ksb.ch	09/2024	
HOCH Health Kantonsspital St. Gallen SAG-TCCS	Swiss Austrian German - Testicular cancer cohort study. Sub-study: PROPHET (Claraspital) Sub-study: microRNA (LUKS)	Prof. Sacha Rothschild Sacha.Rothschild@ksb.ch Susan Groth Susan.Groth@ksb.ch	Q2/2024	
HOCH Health Kantonsspital St. Gallen REVEAL	Swiss real world registry for first line combination treatment of Enfortumab Vedotin and Pembrolizumab in metastatic urothelial cancer – REVEAL. Retrospective inclusion possible.	Dr. Andreas Erdmann Andreas.Erdmann@ksb.ch Dr. Alena Belohlavek Alena.Belohlavek@ksb.ch	06/2025	
PIONEER OPTICS: EKNZ 2022-00344 / EKNZ 2023- 00264	Randomized controlled trial for the evaluation of the Transabdominal Lumbar Approach (TALA) for Robotic Renal Surgery (Hefermehl, Bieri, Heining)	PD Dr. Lukas Hefermehl Lukas.Hefermehl@ksb.ch	2023	01/2026
Active Surveillance bei Prostata-Ca EKNZ 2014-093	Active Surveillance beim Prostatakarzinom: eine Evaluation von Patientendaten am Kantonsspital Baden.	PD Dr. Lukas Hefermehl Lukas.Hefermehl@ksb.ch	2014	
EKNZ BASEC 2016-01424	Prospective Evaluation of Focal Therapy using High Intensity Focused Ultrasound (HIFU) for Localized Prostate Cancer.	PD Dr. Lukas Hefermehl Lukas.Hefermehl@ksb.ch	2016	

Sponsor Study Name	Title	Principal Investigator Clinical Research Coordinator	Studien- eröffnung	Ende Einschluss
PCO	PCO (Prostate Cancer Outcome)-Studie: www.pco-study.com; im Rahmen des Tumorzentrums, zuständig Dr. P. Maletzki. OnkoZert GmbH, Gartenstraße 24, D-89231 Neu-Ulm, Sebastian Dieng, Leitung XML-OncoBox	PD Dr. Lukas Hefermehl Lukas.Hefermehl@ksb.ch	09/2017	
SILENT-EMPIRE	Mikrobiom-Studie bei Urothelkarzinom	PD Dr. Lukas Hefermehl Lukas.Hefermehl@ksb.ch	03/2023	
PIC-PPAT	Prostatakarzinom-Studie	PD Dr. Lukas Hefermehl Lukas.Hefermehl@ksb.ch	10/2024	03/2026
PIC-Single Cell Analysis	Prostatabiopsie-Studie	PD Dr. Lukas Hefermehl Lukas.Hefermehl@ksb.ch	12/2023	
Pfizer C2321008 MEVPRO-3	A phase 3, randomized, double blind, placebo-controlled study of Mevrometostat with Enzalutamide in mHSPC.	Dr. Andreas Erdmann Andreas.Erdmann@ksb.ch Dr. Alena Belohlavek Alena.Belohlavek@ksb.ch	18.05.2026	
SCI 001 TerbinaPro	Terbinafine for biochemically recurrent prostate cancer (TerbinaPro) - A phase II drug-repurposing Study.	Dr. Andreas Erdmann Andreas.Erdmann@ksb.ch Dr. Alena Belohlavek Alena.Belohlavek@ksb.ch	18.05.2026	
Viszeralonkologische Karzinome				
SwissNET Schweizer Register für Neuroendokrine Tumore	Aufklärung über die Weiterverwendung/Nutzung von biologi-schem Material und gesundheitsbezogenen Daten für die biome-dizinische Forschung	Dr. Priska Bützberger Priska.Buetzberger@ksb.ch Beatrice Walter Beatrice.WalterHoerler@ksb.ch	04/2019	10.06.2025
NETest USB	Impact on clinical management of a novel blood-derived liquid biopsy (NETest) in patients with neuroendocrine tumors	Dr. Raphael Delaloye Raphael.Delaloye@ksb.ch Susan Groth Susan.Groth@ksb.ch	19.04.2023	24.07.2025

Sponsor Study Name	Title	Principal Investigator Clinical Research Coordinator	Studien- eröffnung	Ende Einschluss
FrailtyStudy24	Assessment and specialized management of frailty according to the Swiss Frailty Network and Repository Frailty Index among patients undergoing pancreatic and colorectal resections	Prof. Antonio Nocito Antonio.Nocito@ksb.ch PD Dr. Andrea Wirsching Andrea.Wirsching@ksb.ch	01.01.2024	
ToPanc Trial	Survival after Total versus partial Pancreaticoduodenectomy for adenocarcinoma of the pancreatic head, distal cholangiocarcinoma, and ampullary cancer: a multi-centric randomized controlled trial.	Prof. Antonio Nocito Antonio.Nocito@ksb.ch Dr. Pascal Herzog Pascal.Herzog@ksb.ch	01.10.2025	
Radioonkologische Studien				
Gastrointestinale Karzinome				
SCI 89/24	Assessing physicians and cancer patients' preferences for quality of life (QoL) and length of life (LoL) in oncology: A study in gastric and esophageal cancer.	Dr. Stefanie Pederiva Stefanie.Pederiva@ksb.ch Susan Groth Susan.Groth@ksb.ch	04.09.2025	
SCI 41/23 PARTACER-Suisse	Primary and acquired resistance to targeted treatment in BRAF V600E-mutated metastatic colorectal cancer.	Dr. Stefanie Pederiva Stefanie.Pederiva@ksb.ch Susan Groth Susan.Groth@ksb.ch	17.11.2025	
Allgemeine Studien				
Universitätsspital Basel ISCA-Check	Safety and modulation of adaptive immunity by Iscador® Qu Viscum Album extract in patients with advanced, recurrent or metastatic cancers treated with immune checkpoint inhibitors.	Prof. Sacha Rothschild Sacha.Rothschild@ksb.ch Severine Miszak SeverineDominique.Miszak@ksb.ch	27.06.2024	
HOCH Health Kantonsspital St. Gallen MACE	Major adverse cardiovascular events in cancer patients during and after treatment with immune checkpoint inhibitors.	Prof. Sacha Rothschild Sacha.Rothschild@ksb.ch Tanja Bleiker Tanja.Bleiker@ksb.ch	27.07.2025	

Sponsor Study Name	Title	Principal Investigator Clinical Research Coordinator	Studien- eröffnung	Ende Einschluss
Universitätsspital Basel CARE-Insights	Cancer and realistic expectations – Insights into prognostic understanding, preferences, inequalities, needs, support, and empowerment for patients and family members.	Prof. Sacha Rothschild Sacha.Rothschild@ksb.ch Dr. Birthe Lohmann Birthe.Lohmann@ksb.ch		
UniversitätsSpital Zürich Amyloidose Registry	Amyloidosis in Switzerland – A data collection.	Prof. Harald Seeger Harald.Seeger@ksb.ch Dr. Birthe Lohmann Birthe.Lohmann@ksb.ch	05.2026	
Inselspital ParOP	Paracetamol in addition to WHO Step III opioids in chronic cancer pain control – a randomized, double-blind, placebo-controlled, non-inferiority study	Prof. Maria Wertli Maria.Wertli@ksb.ch Susan Groth Susan.Groth@ksb.ch	05.03.2024	03/2026